

Curriculum Vitae

Grazyna Kwapiszewska Professor, Dr. hum. biol.

University Education

- 2018 - 2019 Open innovation in Science, LBG, Vienna, Austria
- 2015 Habilitation (Molecular Pathology) at the Medical University of Graz, Austria
- 2001 - 2005 PhD thesis (Suma Cum Laude) at the Department of Pathology, Justus Liebig University, Giessen, Germany
- 1996 - 2001 Master Degree in Department of Molecular Biology and Biotechnology at Adam Mickiewicz University, Poznan, Poland

Scientific Career

- 2021- present Speaker of the doctoral school Resplmmun
- 2021- present 1st deputy chair of the Physiology Department, Medical University of Graz, Austria
- 2021- present W3 Professorship Institute for Lung Health (partial position), Giessen, Germany
- 2020- present Endowed Professorship at the Department of Physiology, Medical University of Graz, Austria
- 2018 - present Steering committee member of Otto-Loewi-Research Centre, Graz, Austria
- 2017 - present Director and Group Leader, Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria
- 2016 - 2021 Associated faculty member of DK-MOLIN, Medical University of Graz, Austria
- 2016 - present Faculty member, PhD Program MolMed (Molecular Medicine), Medical University of Graz, Austria
- 2012 - present Tutor in PhD Programs, Medical University of Graz, Austria
- 2011 - 2017 Deputy Director and Group Leader, Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria
- 2008 - 2010 Deputy Director, International Graduate Program MBML (Molecular Biology and Medicine of the Lung), Giessen, Germany
- 2008 - 2010 Faculty Member at the University of Giessen Lung Centre, Giessen, Germany
- 2005 - 2008 Teaching Associate, International Graduate Program MBML, Giessen, Germany
- 2005 - 2008 Post-Doctoral Trainee, University of Giessen Lung Centre, Giessen, Germany

Awards and Honors

- 2018, 2021 Best reviewer award from ARJCMB
- 2016 Scientist of the year at the Medical University Graz
- 2009 Rene-Baumgart Foundation Research Award
- 2009, 2011 Poster Prize from German Society of Pathology and PH-DACH
- 2008 Junior Researcher/Investigator Travel Award (4th World Symposium on PH)
- 2007, 2006 Young scientist sponsorship for ERS Congress
- 2000, 2001 Polish Ministry of Education Scholarship

Citation Record

Total citations: 3457; h-index: 34 (Web of Science July 25th, 2022)

Top-10 selected Publications

Jandl K, Marsh LM, Mutgan AC, Crnkovic S, Valzano F, Zabini D, Hoffmann J, Foris V, Gschwandtner E, Klepetko W, Prosch H, Flick H, Brcic L, Kern I, Heinemann A, Olschewski H, Kovacs G, Kwapiszewska G. Impairment of the NKT-STAT1-CXCL9-axis contributes to vessel fibrosis in pulmonary hypertension due to lung fibrosis, *Am J Respir Crit Care Med*. 2022 Jun 28. doi: [10.1164/rccm.202201-0142OC](https://doi.org/10.1164/rccm.202201-0142OC).

Birnhuber A, Jandl K, Biasin V, Fließner E, Valzano F, Marsh LM, Krolczik C, Olschewski A, Wilhelm J, Toller W, Heinemann A, Olschewski H, Wygrecka M, Kwapiszewska G. Pirfenidone exacerbates Th2-driven vasculopathy in a mouse model of SSc-ILD. *Eur Respir J*. 2022 Mar 24;2102347. doi: [10.1183/13993003.02347-2021](https://doi.org/10.1183/13993003.02347-2021)

El Agha, E, Moiseenko A, Kheirollahi V, De Langhe S, Crnkovic S, Kwapiszewska G, Kosanovic D, Schwind F, Schermuly RT, Henneke I, MacKenzie B, Quantius J, Herold S, Ntokou A, Ahlbrecht K, Morty RE, Günther A, Seeger W, Bellusci, S. Two-way conversion between lipogenic and myogenic fibroblastic phenotypes marks the progression and resolution of lung fibrosis. *Cell Stem Cell* 2017; 20(2):261-73.e3. doi: [10.1016/j.stem.2016.10.004](https://doi.org/10.1016/j.stem.2016.10.004).

Birnhuber A, Crnkovic S, Biasin V, Marsh LM, Odler B, Sahu-Osen A, Stacher-Priehse E, Brcic L, Schneider F, Cikes N, Ghanim B, Klepetko W, Graninger W, Allanore Y, Eferl R, Olschewski A, Olschewski H, Kwapiszewska G. IL-1 receptor blockade skews inflammation towards Th2 in a mouse model of systemic sclerosis. *Eur Respir J*. 2019 Sep 29;54(3). pii: 1900154. doi: [10.1183/13993003.00154-2019](https://doi.org/10.1183/13993003.00154-2019)

Kheirollahi V, Wasnick RM, Biasin V, Vazquez-Armendariz AI, Chu X, Moiseenko A, Weiss A, Wilhelm J, Zhang JS, Kwapiszewska G, Herold S, Schermuly RT, Mari B, Li X, Seeger W, Günther A, Bellusci S, El Agha E. Metformin induces lipogenic differentiation in myofibroblasts to reverse lung fibrosis. *Nat Commun*. 2019 Jul 5;10(1):2987. doi: [10.1038/s41467-019-10839-0](https://doi.org/10.1038/s41467-019-10839-0).

Crnkovic S, Egemnazarov B, Damico R, Marsh LM, Nagy BM, Douschan P, Atsina K, Kolb TM, Mathai SC, Hooper JE, Ghanim B, Klepetko W, Fruhwald F, Lassner D, Olschewski A, Olschewski H, Hassoun PM, Kwapiszewska G. Disconnect between Fibrotic Response and Right Ventricular Dysfunction. *Am J Respir Crit Care Med*. 2018 Dec 17. doi: [10.1164/rccm.201809-1737OC](https://doi.org/10.1164/rccm.201809-1737OC)

Kwapiszewska G, Gungl A, Wilhelm J, Marsh LM, Puthenparampil HT, Sinn K, Didiasova M, Klepetko W, Kosanovic D, Schermuly RT, Wujak L, Weiss B, Schaefer L, Schneider M, Kreuter M, Olschewski A, Seeger W, Olschewski H, Wygrecka M. Transcriptome profiling reveals the complexity of pirfenidone effects in IPF. *Eur Respir J*. 2018 Aug 30. pii: 1800564. doi: [10.1183/13993003.00564-2018](https://doi.org/10.1183/13993003.00564-2018)

Marsh LM, Jandl K, Grünig G, Foris V, Bashir M, Ghanim B, Klepetko W, Olschewski H, Olschewski A, Kwapiszewska G. The inflammatory cell landscape in the lungs of patients with idiopathic pulmonary arterial hypertension. *Eur Respir J*. 2018 Jan 25;51(1). doi: [10.1183/13993003.01214-2017](https://doi.org/10.1183/13993003.01214-2017)

Hoffmann J, Wilhelm J, Marsh LM, Ghanim B, Klepetko W, Kovacs G, Olschewski H, Olschewski A, Kwapiszewska G. Distinct differences in gene expression patterns in pulmonary arteries of COPD and IPF patients. *Am J Respir Crit Care Med*. 2014 Jul 1;190(1):98-111. doi: [10.1164/rccm.201401-0037OC](https://doi.org/10.1164/rccm.201401-0037OC)

Seimetz M, Parajuli N, Pichl A, Veit F, Kwapiszewska G, Weisel FC, Milger K, Egemnazarov B, Turowska A, Fuchs B, Nikam S, Roth M, Sydykov A, Medebach T, Klepetko W, Jaksch P, Dumitrescu R, Garn H, Voswinckel R, Kostin S, Seeger W, Schermuly RT, Grimminger F, Ghofrani HA, Weissmann N. Inducible NOS inhibition reverses tobacco-smoke-induced emphysema and pulmonary hypertension in mice. *Cell*. 2011 Oct 14;147(2):293-305. doi: [10.1016/j.cell.2011.08.035](https://doi.org/10.1016/j.cell.2011.08.035).